Iambic Therapeutics, Inc.

IAM Nasdaq SEC CIK 1997038
Follow Iambic Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $11.4M +141.9% vs same quarter last year
Net income −$38.5M −79.5% vs same quarter last year
EPS, diluted −$8.52 −62.6% vs same quarter last year
Operating income −$30.1M −33.1% vs same quarter last year
Revenue by quarter
$4.7M
$11.4M
Q3 25 Q3 26

Source: SEC XBRL filings · latest filing